Reaktionsgleichung
[CH:1]1([N:6]2[CH2:12][C:11]([F:14])([F:13])[C:10](=[O:15])[N:9]([CH3:16])[C:8]3[CH:17]=[N:18][C:19]([NH:21][C:22]4[C:30]([O:31][CH3:32])=[CH:29][C:25]([C:26]([OH:28])=O)=[C:24]([F:33])[CH:23]=4)=[N:20][C:7]2=3)[CH2:5][CH2:4][CH2:3][CH2:2]1.[CH3:34][N:35]1[CH2:40][CH2:39][N:38]([C:41]2[CH:47]=[CH:46][C:44]([NH2:45])=[CH:43][CH:42]=2)[CH2:37][CH2:36]1>>[CH:1]1([N:6]2[CH2:12][C:11]([F:13])([F:14])[C:10](=[O:15])[N:9]([CH3:16])[C:8]3[CH:17]=[N:18][C:19]([NH:21][C:22]4[C:30]([O:31][CH3:32])=[CH:29][C:25]([C:26]([NH:45][C:44]5[CH:43]=[CH:42][C:41]([N:38]6[CH2:37][CH2:36][N:35]([CH3:34])[CH2:40][CH2:39]6)=[CH:47][CH:46]=5)=[O:28])=[C:24]([F:33])[CH:23]=4)=[N:20][C:7]2=3)[CH2:5][CH2:4][CH2:3][CH2:2]1Komponenten
3
Edukt 2
Produkt 1
Versuchsvorschrift
The title compound was prepared in a manner analogous to compound 149 from 4-(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[5,4-b][1,4]diazepin-2-ylamino)-2-fluoro-5-methoxybenzoic acid and 4-(4-methylpiperazin-1-yl)aniline with yield 82 mg (53%). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.61 (br. s., 4 H) 1.73 (br. s., 2 H) 1.99 (br. s., 2 H) 2.22 (s, 3 H) 2.45 (br. s., 4 H) 3.09 (br. s., 4 H) 3.94 (s, 3 H) 4.08 (t, J=13.89 Hz, 2 H) 4.84 (br. s., 1 H) 6.91 (d, J=8.84 Hz, 2 H) 7.26 (d, J=6.32 Hz, 1 H) 7.56 (d, J=8.59 Hz, 2 H) 8.08 (s, 1 H) 8.18-8.41 (m, 2 H) 9.91 (br. s., 1 H). [M+H] calc'd for C32H37F3N8O3, 639; found 639.
Quellen und Nachweise
- ORD-Eintrag
- ord-f1d8547200314a0c82e0ff061d31c0ec
- Quelldatensatz
- uspto-grants-2012_11
- Patentnummer
- US08318727B2
Verknüpfte Notizen
Wird geladen…